Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ABCG2 | Q9UNQ0 | 10/20 | 0.65 |
| ▸ | NPC1 | O15118 | 4/20 | 0.55 |
| ▸ | RAB9A | P51151 | 4/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.55 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.55 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | HTT | P42858 | 1/20 | 0.46 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14474455 | 0.93 | MEN1 (0.62) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474150 | 0.92 | ABCG2 (0.65) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474059 | 0.91 | NPC1 (0.57) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474921 | 0.91 | ABCG2 (0.60) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474024 | 0.90 | RAB9A (0.56) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474424 | 0.90 | ABCG2 (0.61) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474453 | 0.90 | MAPT (0.56) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14726452 | 0.90 | NPC1 (0.55) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474408 | 0.89 | RAB9A (0.58) | ABCG2NPC1RAB9AMEN1KMT2A | |
| SCHEMBL14474494 | 0.88 | ABCG2 (0.56) | ABCG2NPC1RAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL COMPANY (JP) | 2013-02-28 | — | — | US | disclosed |
| WO-2013003586-A1 | QUINAZOLINES AS THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-01-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053341-A1 | THERAPEUTIC COMPOUNDS AND RELATED METHODS OF USE | PPP4C, PPP3CB, PTPRG | ABCG2 2822/4885NPC1 2982/4885RAB9A 1248/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.